NIAID Banner Logo Image

TB Drugs in Development


Drug ClassCompanyDrug NameAlt NameDrug StatusNotesAIDS#
Antibody, MonoclonalNational University, SingaporePascolizumabAnti-IL-4 AntibodyPhase 2Ongoing 
Cell Wall Synthesis InhibitorMichael Hoelscher, Ludwig-Maximilians,University of MunichBTZ043 Phase 1Completed 538411
Cell Wall Synthesis InhibitorGlobal Alliance for TB Drug DevelopmentTBA-354 Phase 1Terminated 510946
Cell Wall Synthesis InhibitorUniversity Medical Center GroningenInvanz™ErtapenemPhase 2Completed 604819
Cell Wall Synthesis InhibitorGlobal Alliance for TB Drug DevelopmentTBA-7371 Phase 1Completed 555726
Cell Wall Synthesis InhibitorAsubio PharmaFarom™FaropenemPhase 2Completed 545326
Cell Wall Synthesis InhibitorSequellaSQ-109 Phase 2Completed 207396
Cell Wall Synthesis InhibitorOtsuka PharmOPC-167832  Phase 1/2Recruiting 
Cell Wall Synthesis InhibitorJohns Hopkins University Merrem™Meropenem; SM-7338Phase 2Completed 007788
Cell Wall Synthesis InhibitorNearmedic Plus LLCMacozinoneMCZ; PBTZ-169Phase 2Terminated 573761
CombinationGlobal Alliance for TB Drug DevelopmentBPaMZBedaquiline and Pretomanid and Moxifloxacin and PyrazinamidePhase 2/3Recruiting 
Cytochrome bc1 Complex InhibitorQurient Co., Ltd.Telacebec Q203Phase 2Active, Not Recruiting 594207
DNA Replication Inhibitor/TB Cell Division InhibitorBayerFlagyl™Metronidazole; Bayer 5360; Clont; Danizol; Gineflavir; Metric 21; Trichazol; Trichopal; Trivazol; VagilenPhase 2Completed 007953
DNA Replication Inhibitor/TB Cell Division InhibitorParke-Davis; Kyorin Pharm; PfizerTequin™Gatifloxacin; GTFX; BMS-206584; AM-1155; CG 5501; PD-135432; GATPhase 1/2Completed 044913
DNA Replication Inhibitor/TB Cell Division InhibitorDaiichi Pharm; Sanofi-Aventis; Ortho-McneilLevaquin™; Tavanic™S-(-)-Ofloxacin; DR-3355; RWJ-25213; Cravit; L-Ofloxacin; Levofloxacin; LVXPhase 3Completed 002307
DNA Replication Inhibitor/TB Cell Division InhibitorBayer; Schering-Plough Avelox™Moxifloxacin; MXFX; BAY 12-8039; Actira; AveloxPhase 3Completed 070017
GyrB ATPase InhibitorSpero Therapeutics, LLCSPR720 Phase 1Recruiting 
Host-directed TherapyJohns Hopkins University Pravastatin Phase 2Not Yet Recruiting 488445
Intracellular NO ReleasePathogenesis Corp; ChironPretomanidPA-824New Drug Application (NDA) Submitted (March 2019)  007331
Leucyl-tRNA Synthetase (LeuRS) InhibitorGlaxoSmithKlineGSK3036656GSK070Phase 2Not Yet Recruiting 599488
Mycolic acid Biosynthesis InhibitorOtsuka PharmDeltyba™Delamanid; OPC-67683Phase 3Completed 182259
Protein Synthesis InhibitorMicuRx PharmaceuticalsMRX-4Prodrug of Contezolid (MRX-1)Phase 1Completed 
Protein Synthesis Inhibitor/TB Growth InhibitorPharmacia & Upjohn, Inc.; PfizerSutezolidPNU-100480; PF-02341272; OxazolidininonePhase 2Completed 045415
Protein Synthesis Inhibitor/TB Growth InhibitorPharmacia & Upjohn, Inc.; PfizerZyvox™Linezolid; PNU-100766; LZDPhase 3Recruiting 070944
Protein Synthesis Inhibitor/TB Growth InhibitorAstraZenecaPosizolidAZD2563; AZD-5847Phase 2Completed 554767
Protein Synthesis Inhibitor/TB Growth InhibitorLegoChem Biosciences, Inc.DelpazolidLCB01-0371Phase 2Recruiting 581214
Protein Synthesis Inhibitor/TB Growth InhibitorGlobal Alliance for TB Drug DevelopmentTBI-223 Phase 1Recruiting 592820
Pyruvate-Ferredoxin Oxidoreductase InhibitorWeill Medical College of Cornell UniversityAlinia™ ; Nizonide™NitazoxanidePhase 2Completed 057131
UnidentifiedScientific Center for Anti-infectious Drugs, KazakhstanFS-1Molecular iodine complex with bioorganic ligands, magnesium and lithium halogenidesPhase 3Recruiting 

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: May 2019